TVGN•benzinga•
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
Summary
D Boral Capital initiates Buy on Tevogen Bio citing its scalable T-cell therapies and upcoming clinical readouts, with a $10 price target.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 4, 2025 by benzinga